In four patients with severe autoimmune disease, teclistimab, a bispecific antibody to B-cell maturation antigen and CD3, resulted in autoantibody reduction and clinical response after short-term follow-up.
No takes yet. Share an insight, caveat, or question.
Hagen et al. (2024) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: